Idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease. IPF is more common in elderly patients and over time as healthy lung tissue is replaced by altered extracellular matrix (fibrosis) the alveolar architecture is destroyed, leading to decreased lung function and finally respiratory failure and death.
Featured Learning Zones
Find out more about IPF in the disease awareness section, such as epidemiology, pathophysiology, symptoms and diagnosis. Learn about the latest interventions available for patients in the treatment section, including treatment pathways and guideline recommendations.
EAACME accredited CME
Recognising and optimising care of IPF
Are you familiar with the symptoms of idiopathic pulmonary fibrosis (IPF)? Learn more about how to definitively diagnose IPF and find out how early diagnosis can benefit your patients. Plus improve your knowledge of the treatment options available to patients with IPF.
Receive 1 European CME credit (ECMEC®) for successful completion.
Accreditation date 16th March 2020.
Although the cause of IPF is not clear, smoking, viral infections and previous family history of the condition are contributing factors. Patients with IPF often have chronic exertional dyspnoea, bibasilar lung crackles (‘Velcro’ crackles) and finger clubbing. Physicians should consider IPF in patients with these signs and a definitive diagnosis can be made based on characteristic imaging and histological patterns.
Treating IPF includes pharmacological and pulmonary rehabilitation approaches. Effective disease-modifying treatments are available which is why it is important to diagnose and treat IPF as early as possible. In extreme cases of IPF a lung transplant may be needed.
To find out how to recognise and treat idiopathic pulmonary fibrosis, visit our dedicated Learning Zone which contains further information and expert opinion on diagnosis and current IPF treatment guidelines.
Related news and insights
FibroGen, Inc.announced dosing of the first patient in the ZEPHYRUS-2 Phase III clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) , a chronic, progressive, and fatal lung disease.
Boehringer Ingelheim announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).
<strong>Background: </strong>This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society...